Fibromyalgia Disease Burden in Mothers of Children With Attention-Deficit/Hyperactivity Disorder
Is the Disease Burden of Fibromyalgia Syndrome Higher in Mothers of Children With Attention-Deficit/Hyperactivity Disorder? A Prospective Controlled Study
Sultan 1. Murat State Hospital
100 participants
Dec 26, 2025
OBSERVATIONAL
Conditions
Summary
In this study, the investigators aimed to evaluate the impact of having a child diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) on parental disease burden in mothers diagnosed with Fibromyalgia Syndrome (FMS). The study will include 50 mothers with FMS who have a child diagnosed with ADHD and 50 mothers with FMS who have children without any psychiatric disorders. Among mothers of children followed with a diagnosis of ADHD at the Child and Adolescent Psychiatry Outpatient Clinic of Edirne Sultan 1st Murat State Hospital, the presence of widespread body pain will be assessed. Mothers reporting widespread body pain will be referred to the Pain Management Outpatient Clinic of the same hospital for further evaluation for FMS. Mothers diagnosed with FMS will be included in the study group. The comparison group will consist of mothers with FMS who have children without any psychiatric disorders. These participants will be selected from patients diagnosed with FMS who present to the Pain Management Outpatient Clinic of Edirne Sultan 1st Murat State Hospital.
Eligibility
Inclusion Criteria8
- Being a female aged between 18 and 50 years
- Having one or more children aged 6-17 years diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) according to DSM-5 diagnostic criteria
- Having a diagnosis of Fibromyalgia Syndrome (FMS according to the 2016 American College of Rheumatology \[ACR\] criteria)
- Being literate
- Being a female aged between 18 and 50 years
- Having one or more children aged 6-17 years without any psychiatric disorders
- Having a diagnosis of Fibromyalgia Syndrome (FMS) according to the 2016 American College of Rheumatology (ACR) criteria
- Being literate
Exclusion Criteria9
- Receiving regular pharmacological treatment for Fibromyalgia Syndrome
- Having an active psychiatric disorder or using psychiatric medication
- Having a history of infectious disease, chronic inflammatory disease, or malignancy
- Being pregnant or breastfeeding
- Having a central or peripheral nervous system disorder (e.g., cerebrovascular disease, multiple sclerosis)
- Being uncooperative during clinical evaluation
- Having comorbid conditions that may affect quality of life, including congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes mellitus, or peripheral vascular disease
- Having a diagnosis of hypothyroidism or hyperthyroidism
- Having substance use disorder or alcohol use disorder
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The demographic characteristics of the participants included in the study-age, educational level, occupation, socioeconomic status, marital status, number of children, and number of children diagnosed with ADHD-will be recorded, and body mass index (BMI) will be calculated. The duration of symptoms will be assessed in months. Pain intensity in all patients will be evaluated using the Visual Analog Scale (VAS). To assess quality of life and functional status, the Fibromyalgia Impact Questionnaire (FIQ), which has demonstrated validity and reliability in Turkish, will be administered. Levels of central sensitization will be assessed using the Central Sensitization Inventory (CSI), which has been validated and shown to be reliable in Turkish.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07327775